glp-1 price cut news november 2025 Trump Administration Unveils Plan to Make Drugs Affordable GLP-1 Weight-Loss Drug Demonstration Begins

2020 safety paper is considered essential reading for any researcher evaluating this compounds translational potential

Ipamorelin peptide is studied in laboratory environments for its interaction with ghrelin receptor pathways and endocrine-related signaling systems

Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1)

Association between glucagon-like peptide-1 agonists and risk of diabetic retinopathy: a disproportionality analysis using FDA adverse event reporting system data

Kumar says that more research is needed to understand what drives these effects, and GLP-1s are not currently FDA-approved to treat addiction disorders